Acorda Therapeutics (NSDQ:ACOR) announced today that its chief of business operations, David Lawrence, is resigning from the company. Lawrence, who also serves as Acorda’s principal accounting and financial officer, is resigning effective mid-March 2021 as he is set to take a leadership position at an early-stage biotechnology company, according to a news release. “Dave has […]
Personnel Moves
Lyra Therapeutics names new chief medical officer
Lyra Therapeutics (NSDQ:LYRA) announced today that it appointed Dr. Robert Kern as its new chief medical officer. Kern will remain in his current position as the George A. Sisson Professor and Chair, Department of Otolaryngology – Head and Neck Surgery at the Northwestern University Feinberg School of Medicine while operating as Lyra’s CMO, according to […]
Dyve Biosciences appoints Camilla V. Simpson to its board
Clinical-stage biotechnology company Dyve Biosciences announced this week that Camilla V. Simpson joined its board of directors. Simpson possesses over 25 years of experience in the biotech industry, currently serving as an independent member of the board of directors at Spruce Biosciences and as a member of the scientific advisory board at Aristea Therapeutics, according […]
Bigfoot Biomedical appoints commercial team
Bigfoot Biomedical announced today that it established a team led by Berkley Nelson to lead the company’s sales effort. Bigfoot is marketing its the recently FDA-cleared Bigfoot Unity real-time, dose-decision support system, which uses smartpen caps and integrates Abbott’s FreeStyle Libre 2 continuous glucose monitoring platform. Get the full story at our sister site, MassDevice.
Delcath names new CEO
Delcath Systems (OTC:DCTH) announced that it appointed Gerard Michel as its new CEO, effective yesterday, Oct. 1, 2020. Michel assumed the role yesterday and also was appointed as a Class I director on the company’s board of directors, with that role continuing until the expiry of his term at the company’s 2022 annual meeting of stockholders, […]
Monarch Medical Technologies appoints diabetes tech veteran as new CEO
Monarch Medical Technologies announced that it appointed industry veteran Raymie McFarland as its new president & CEO. As McFarland takes over day-to-day management, Brian Duffy and Christophe Mallard, two of the Charlotte, N.C.-based diabetes technology company’s board members, will relinquish their respective roles as interim CEO and interim president. McFarland spent the previous nine years […]
Former Eli Lilly researcher joins Bigfoot Biomedical as chief medical officer
Bigfoot Biomedical has brought on Dr. Jim Malone — a 21-year clinical research veteran at Eli Lilly & Co. — as its chief medical officer, the diabetes treatment tech company said today. Malone, an endocrinologist specializing in diabetes, also spent 12 years in clinical practice. “Jim’s blended experience in medical practice and device development bring […]
B. Braun’s top North American executive to retire
B. Braun announced today that Caroll H. Neubauer will retire at the end of August after 24 years leading the Melsungen, Germany–based medical and drug delivery device giant’s North America operations. Jean-Claude Dubacher, a former Johnson & Johnson and Abbott executive who already took over Neubauer’s role as CEO of B. Braun Medical at the […]
Dyve Biosciences hires new chief scientific officer
Transdermal drug therapy developer Dyve Biosciences announced that it appointed longtime Pfizer executive Chuck Harbert to the role of chief scientific officer. Harbert spent three decades at Pfizer, serving as the company’s VP of U.S. exploratory development and strategic planning, among other senior positions with Pfizer Central Research. He is the inventor and co-inventor of 35 pharmaceutical […]
PsiOxus Therapeutics shuffles the deck
PsiOxus Therapeutics shuffles the deck PsiOxus said it named Dr. Charles Morris as its chief development officer and Karen LaRochelle as its chief business officer. Morris comes from ImmunoGen, where he was chief development officer, bringing its lead candidate to Phase III development. Most recently, LaRochelle was the executive director of global business development at […]
